Brandl & Talos advises shareholders on the sale of Themis to Merck Sharp Dohme
With this acquisition, Merck Sharp Dome (MSD) is securing, among other things, the COVID-19 vaccine developed by the Austrian company Themis, which will be combined with an MSD vaccination platform, thus contributing to the global fight against coronavirus.
The Austrian company Themis is a leader in the development of vaccines against immune diseases and has been in the hands of several international investors. Today, MSD announced the acquisition of the company. MSD is combining its vaccine platform with a new vaccine against COVID-19, developed by Themis and Institut Pasteur (a European vaccine research institute). This transaction paves the way for Austria’s contribution to the worldwide fight against the coronavirus.
Brandl & Talos advised Themis’ shareholders on this landmark deal for the Austrian biotech scene. The prestigious rooster of shareholders includes Farallon Capital Management, Global Health Investment Fund, Adjuvent Capital, Wellington Partners Life Sciences, Ventech, Omnes-Fonds, Hadean Ventures, and aws Gründerfonds. In addition, Wilson Sonsini Goodrich & Rosati (Robert Ishii & Miranda Biven) advised the shareholders on US law issues.
Themis Bioscience GmbH was represented by McDermott Will & Emery France (Emmanuelle Trombe & David Lipkin) and Herbst Kinsky (Florian Steinhart & Felix Kernbichler).
MSD was represented by Covington & Burling (Catherine J. Dargan & Michael J. Riella) and Wolf Theiss (Hartwig Kienast).
“This transaction is a prime example of the enormous innovative strength of Austrian biotechnology companies. We have been supporting this scene for years and are pleased that our expertise is being relied upon in this sensational transaction.” – Roman Rericha of Brandl & Talos.
T +43 1 522 5700-82
Photos: Roman Rericha & Markus Arzt